that’s a good point - it’ll be a huge win
2022 - 4 leads with pre-clinical data work-up as per RP11 quality. VP-001, IND approved by FDA, enters clinic - phase 1 - first patient milestone
2023 - OPA1 IND approved, first patient enrolled. RP11 efficacy read outs. Hopefully global headlines. Lead 3/4 IND closer to roadmap. Leads 4-8 hopefully defined with pre-clinical data work up.
2024 - early in the year we’ll need some serious $ injection. Maybe we’ll have enough juicy data by then for our platform, and a licensing $ event by then = we got $ needs covered for future pipeline to clinic
Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-31
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.040(3.33%) |
Mkt cap ! $723.2M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.24 | $1.19 | $1.500M | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 204320 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4333 | 2 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |